Lineage Cell Therapeutics: Q1 Earnings Insights


Lineage Cell Therapeutics LCTX reported its Q1 earnings results on Thursday, May 11, 2023 at 04:01 PM.

Here's what investors need to know about the announcement.


Lineage Cell Therapeutics beat estimated earnings by 25.0%, reporting an EPS of $-0.03 versus an estimate of $-0.04.

Revenue was down $2.85 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.01 which was followed by a 2.05% drop in the share price the next day.

Here's a look at Lineage Cell Therapeutics's past performance:

Quarter Q4 2022 Q3 2022 Q2 2022 Q1 2022
EPS Estimate -0.04 -0.03 -0.04 -0.03
EPS Actual -0.03 -0.04 -0.04 -0.04
Revenue Estimate 2.57M 3.90M 3.68M 7.32M
Revenue Actual 1.90M 3.00M 4.55M 5.24M

To track all earnings releases for Lineage Cell Therapeutics visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!